Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The brokerage currently has a $6.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s price target points to a potential upside of 18.11% from […]
Stock Analysts’ upgrades for Wednesday, June 1st: Applied Therapeutics (NASDAQ:APLT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $1.50 target price on the stock. According to Zacks, “Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing drug candidates for unmet […]
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing […]
Equities Research Analysts’ downgrades for Tuesday, May 24th: Apollo Investment (NASDAQ:AINV) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Apollo Investment Corporation is a closed-end investment company that has elected to be treated as a business development company under the Investment Company Act of […]
Investment Analysts’ upgrades for Wednesday, May 25th: Afya (NASDAQ:AFYA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $12.00 price target on the stock. According to Zacks, “Afya Limited is a medical education group primarily in Brazil. Afya Limited is based in NEW […]